GoldBamboo.com - Knowledge is strong medicine
  

A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT - Article


  Not Signed In - Sign In / Register






Zalcitabine

ddC; dideoxycytidine; Hivid


Clinical Trial: A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT

This study has been completed.

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

PRIMARY: To determine safety, tolerance, and pharmacokinetics of zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) when given in combination in clinically stable AZT-treated children. SECONDARY: To compare combination therapy with mono drug therapy for antiviral activity and laboratory markers of disease progression, as determined by virologic and immunologic determinations. To evaluate the influence of combination therapy on disease progression as determined by evaluation of clinical criteria. In children currently being treated with AZT, it is unknown whether the addition of another antiretroviral agent such as ddC would help increase efficacy and tolerance. This study will examine the possible advantages of combination AZT/ddC therapy over monotherapy with AZT alone.

Condition Treatment or Intervention Phase
HIV Infections
 Drug: Zidovudine
 Drug: Zalcitabine
Phase II

MedlinePlus related topics:  AIDS

Study Type: Interventional
Study Design: Treatment

Official Title: A Phase II Study to Evaluate Pharmacokinetics, Safety, Tolerance and Activity of Dideoxycytidine (ddC) Administered in Combination with Zidovudine (AZT) in Stable, AZT-Treated Pediatric Patients with HIV Infection

Further Study Details: 

Expected Total Enrollment:  180

In children currently being treated with AZT, it is unknown whether the addition of another antiretroviral agent such as ddC would help increase efficacy and tolerance. This study will examine the possible advantages of combination AZT/ddC therapy over monotherapy with AZT alone.

Patients are stratified according to duration of ongoing AZT therapy and are randomized to receive AZT either alone or in combination with ddC. Patients receive therapy until the last patient enrolled completes 32 weeks of therapy. The study may be extended for two additional 32-week periods on an optional basis.

Eligibility

Ages Eligible for Study:  3 Months   -   12 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Concurrent Medication: Recommended:

  • PCP prophylaxis.

Allowed:

  • Intravenous and/or intramuscular immunoglobulin.
  • Acyclovir (no more than 30 mg/kg/day PO).
  • Ketoconazole (no more than 10 mg/kg/day).
  • Nystatin.
  • Aspirin, acetaminophen, nonsteroidal anti-inflammatory drugs, sedatives, and barbiturates, not to exceed 72 hours.
  • Isoniazid in combination with pyridoxine, provided there is no evidence of peripheral neuropathy.
  • Trimethoprim / sulfamethoxazole.
  • Amphotericin B (no more than 1 mg/kg for 5 days/week).
  • Aerosolized ribavirin for bronchiolitis.
  • Hematopoietic agents.
  • Other drugs with little nephro-, hepato-, or cytotoxicity.
  • Nutritional support for HIV wasting syndrome or malnutrition.

Patients must have:

  • HIV infection.
  • Ongoing stable AZT therapy.

Exclusion Criteria

Co-existing Condition: Patients with the following symptoms and conditions are excluded:

  • Disease progression while on AZT, to the extent that the patient meets the criteria for advanced disease protocols.
  • Known allergy or sensitivity to ddC.
  • Cardiomyopathy.

Concurrent Medication: Excluded:

  • Biologic modifiers other than IVIG, steroids, or hematopoietic agents.
  • Investigational medications unless approved by protocol chair.
  • Medications known to cause pancreatitis (unless ddC is interrupted while these medications are given).

Patients with the following prior conditions are excluded:

Prior Medication: Excluded:

  • Antiretroviral agents other than AZT within 2 weeks of study entry.

Required:

  • Ongoing stable AZT therapy for more than 6 weeks duration.

Location Information


Alabama
      Univ of Alabama at Birmingham Schl of Med / Pediatrics, Birmingham,  Alabama,  35294,  United States

California
      UCSF / Moffitt Hosp - Pediatric, San Francisco,  California,  941430105,  United States

      UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla,  California,  920930672,  United States

      San Francisco Gen Hosp, San Francisco,  California,  94110,  United States

      Stanford Univ School of Medicine / Pediatrics, Stanford,  California,  943054149,  United States

      Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles,  California,  905022004,  United States

      Children's Hosp of Oakland, Oakland,  California,  946091809,  United States

      UCLA Med Ctr / Pediatric, Los Angeles,  California,  900951752,  United States

      Cedars Sinai / UCLA Med Ctr, Los Angeles,  California,  900481804,  United States

      Long Beach Memorial (Pediatric), Long Beach,  California,  90801,  United States

      Los Angeles County - USC Med Ctr, Los Angeles,  California,  90033,  United States

Colorado
      Children's Hosp of Denver, Denver,  Colorado,  802181088,  United States

Connecticut
      Yale Univ Med School, New Haven,  Connecticut,  06504,  United States

      Univ of Connecticut / Farmington, Farmington,  Connecticut,  06032,  United States

District of Columbia
      Howard Univ Hosp, Washington,  District of Columbia,  20060,  United States

      Children's Hosp of Washington DC, Washington,  District of Columbia,  200102916,  United States

      Georgetown Univ Med Ctr, Washington,  District of Columbia,  20007,  United States

Florida
      Univ of Miami (Pediatric), Miami,  Florida,  33161,  United States

Georgia
      Emory Univ Hosp / Pediatrics, Atlanta,  Georgia,  30306,  United States

Illinois
      Chicago Children's Memorial Hosp, Chicago,  Illinois,  606143394,  United States

      Cook County Hosp, Chicago,  Illinois,  60612,  United States

      Univ of Illinois College of Medicine / Pediatrics, Chicago,  Illinois,  60612,  United States

      Univ of Chicago Children's Hosp, Chicago,  Illinois,  606371470,  United States

Louisiana
      Tulane Univ / Charity Hosp of New Orleans, New Orleans,  Louisiana,  701122699,  United States

Maryland
      Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore,  Maryland,  21201,  United States

Massachusetts
      Children's Hosp of Boston, Boston,  Massachusetts,  021155724,  United States

      Boston City Hosp / Pediatrics, Boston,  Massachusetts,  02118,  United States

      Baystate Med Ctr of Springfield, Springfield,  Massachusetts,  01199,  United States

      Univ of Massachusetts Med School, Worcester,  Massachusetts,  016550001,  United States

Michigan
      Children's Hosp of Michigan, Detroit,  Michigan,  48201,  United States

New Jersey
      Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl, Newark,  New Jersey,  071072198,  United States

      Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark,  New Jersey,  07103,  United States

New York
      King's County Hosp Ctr / Pediatrics, Brooklyn,  New York,  11203,  United States

      SUNY - Brooklyn, Brooklyn,  New York,  11203,  United States

      North Shore Univ Hosp, Great Neck,  New York,  11021,  United States

      Westchester Hosp, Valhalla,  New York,  10595,  United States

      Schneider Children's Hosp, New Hyde Park,  New York,  11040,  United States

      Univ of Rochester Medical Center, Rochester,  New York,  14642,  United States

      Bellevue Hosp / New York Univ Med Ctr, New York,  New York,  10016,  United States

      Mount Sinai Med Ctr, New York,  New York,  10029,  United States

      Columbia Presbyterian Med Ctr, New York,  New York,  10032,  United States

      Mount Sinai Med Ctr / Pediatrics, New York,  New York,  10029,  United States

      Albert Einstein College of Medicine, Bronx,  New York,  10461,  United States

      Metropolitan Hosp Ctr, New York,  New York,  10029,  United States

      Children's Hosp at Albany Med Ctr, Albany,  New York,  12208,  United States

      SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse,  New York,  13210,  United States

      Bronx Lebanon Hosp Ctr, Bronx,  New York,  10457,  United States

      Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York,  New York,  10032,  United States

      Lincoln Hosp Ctr, Bronx,  New York,  10451,  United States

      Children's Hosp Pact Prog / Children's Hosp of Buffalo, Buffalo,  New York,  14222,  United States

North Carolina
      Duke Univ Med Ctr, Durham,  North Carolina,  277103499,  United States

Ohio
      Columbus Children's Hosp, Columbus,  Ohio,  432052696,  United States

Pennsylvania
      Children's Hosp of Philadelphia, Philadelphia,  Pennsylvania,  191044318,  United States

      Saint Christopher's Hosp for Children, Philadelphia,  Pennsylvania,  191341095,  United States

Rhode Island
      Rhode Island Hosp / Brown Univ, Providence,  Rhode Island,  02903,  United States

South Carolina
      Med Univ of South Carolina, Charleston,  South Carolina,  294253312,  United States

Washington
      Children's Hospital & Medical Center / Seattle ACTU, Seattle,  Washington,  981050371,  United States

Canada, Ontario
      Sunnybrook Health Science Ctr, Toronto,  Ontario,  Canada

Puerto Rico
      San Juan City Hosp, San Juan,  009367344,  Puerto Rico

      Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan,  009365067,  Puerto Rico

      Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon,  00956,  Puerto Rico

Study chairs or principal investigators

S Pahwa,  Study Chair
SS Bakshi,  Study Chair

More Information

Click here for more information about Zidovudine

Click here for more information about Zalcitabine

Publications

Bakshi SS, Britto P, Capparelli E, Mofenson L, Fowler MG, Rasheed S, Schoenfeld D, Zimmer B, Frank Y, Yogev R, Jimenez E, Salgo M, Boone G, Pahwa SG. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team. J Infect Dis. 1997 May;175(5):1039-50.

Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J. 2001 Jan;20(1):40-8.

Study ID Numbers:  ACTG 190
Record last reviewed:  May 1995
Last Updated:  April 7, 2005
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00001032
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005


Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Zalcitabine.

September 7, 2008



Page Updated: June 1, 2005
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.